Arsenic trioxide induces down-regulation of gp46 via protein oxidation: proteomics analysis of oxidative modified proteins in As2O3-treated HTLV-1-infected cells.
Nabeshi
H
H
Laboratory of Pharmaceutical Proteomics, National Institute of Biomedical Innovation, Osaka, Japan.
Yoshikawa
T
T
Kamada
H
H
Shibata
H
H
Sugita
T
T
Abe
Y
Y
Nagano
K
K
Nomura
T
T
Minowa
K
K
Tsunoda
S
S
Tsutsumi
Y
Y
D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D002459:Cell Fusion; D015536:Down-Regulation / Q000187:drug effects; D015180:Electrophoresis, Gel, Two-Dimensional; D000091342:Endoplasmic Reticulum Chaperone BiP; D005782:Gels; D015686:Gene Products, env / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D015490:HTLV-I Infections / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D006868:Hydrolysis; D047468:Immunoprecipitation; D010084:Oxidation-Reduction; D010087:Oxides / Q000494:pharmacology*; D040901:Proteomics; D015682:Retroviridae Proteins, Oncogenic / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014357:Trypsin / Q000737:chemistry
D001152:Arsenicals; D000091342:Endoplasmic Reticulum Chaperone BiP; D005782:Gels; D015686:Gene Products, env; C000717247:HSPA5 protein, human; D010087:Oxides; D015682:Retroviridae Proteins, Oncogenic; C055266:gp46 protein, Human T-cell leukemia virus type I; D014357:Trypsin; D000077237:Arsenic Trioxide